CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER

被引：1
|
作者：
Ubago, R. [1 ]
Castillo, M. A. [1 ]
Flores, S. [2 ]
Rodriguez, R. [1 ]
Beltran, C. [1 ]
机构：
[1] Agencia Evaluac Tecnol Sanitarias Andalucia, Seville, Andalucia, Spain
[2] Andalusian Agcy Hlth & Technol Assessment, Seville, Andalucia, Spain
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1104
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A433 / A434
页数：2
相关论文
共 50 条
  • [41] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [42] First-line treatment strategies for elderly patients with metastatic colorectal cancer
    Meulenbeld, Hielke J.
    Creemers, Geert-Jan
    DRUGS & AGING, 2007, 24 (03) : 223 - 238
  • [43] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [44] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [45] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
    Souza, P., V
    Zanini, F. E.
    Biglia, L., V
    Kim, H. S.
    Fahham, L.
    VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
  • [46] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 837 - 851
  • [47] CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer
    Sunakawa, Yu
    Tsuji, Akihito
    Denda, Tadamichi
    Segawa, Yoshihiko
    Negoro, Yuji
    Shimada, Ken
    Kochi, Mitsugu
    Nakamura, Masato
    Kotaka, Masahito
    Tanioka, Hiroaki
    Takagane, Akinori
    Tani, Satoshi
    Yamaguchi, Tatsuro
    Watanabe, Takanori
    Takeuchi, Masahiro
    Fujii, Masashi
    Ichikawa, Wataru
    TARGETED ONCOLOGY, 2017, 12 (06) : 787 - 794
  • [48] Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
    Putri, Septiara
    Saldi, Siti Rizny F.
    Khoe, Levina Chandra
    Setiawan, Ery
    Megraini, Amila
    Santatiwongchai, Benjarin
    Nugraha, Ryan R. R.
    Permanasari, Vetty Y. Y.
    Nadjib, Mardiati
    Sastroasmoro, Sudigdo
    Armansyah, Armansyah
    BMC CANCER, 2023, 23 (01)
  • [49] CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer
    Yu Sunakawa
    Akihito Tsuji
    Tadamichi Denda
    Yoshihiko Segawa
    Yuji Negoro
    Ken Shimada
    Mitsugu Kochi
    Masato Nakamura
    Masahito Kotaka
    Hiroaki Tanioka
    Akinori Takagane
    Satoshi Tani
    Tatsuro Yamaguchi
    Takanori Watanabe
    Masahiro Takeuchi
    Masashi Fujii
    Wataru Ichikawa
    Targeted Oncology, 2017, 12 : 787 - 794
  • [50] Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
    Septiara Putri
    Siti Rizny F. Saldi
    Levina Chandra Khoe
    Ery Setiawan
    Amila Megraini
    Benjarin Santatiwongchai
    Ryan R. Nugraha
    Vetty Y. Permanasari
    Mardiati Nadjib
    Sudigdo Sastroasmoro
    Armansyah Armansyah
    BMC Cancer, 23 (1)
12345